Page 31 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Interim PET as biomarker of response in HL and DLBCL?
and image reconstruction protocols, as well as comparable data analysis. Quality control and quality assurance procedures are also required to maintain the accuracy and precision of quantification.
Recently, the European Association of Nuclear Medicine (EANM) guidelines for FDG-PET in tumor imaging for trials and clinical practice have been up-dated [7], and an accreditation system is available (EARL; http://earl.eanm.org). Within clinical studies, these changes in SUV are being compared with visual assessment. Besides SUV, metabolically active tumor volume defined with FDG-PET is being investigated.
Interim-PET in Hodgkin lymphoma
Hodgkin lymphoma is a lymphoma entity with cure rates of up to 90%. iPET predicts response early during treatment and PET-guided therapy is a new strategy in development for HL. The goal of current and recently completed
Figure 1. Coronal slices from 5 patients are shown at baseline and response.
The level of uptake at residual sites, where present (arrowed) is graded according to the 5-point Deauville score.
29
2